Overall, treatment was judged as effective (seeSupplementary Table S1for definition) in 89.3% (75/84) of bleeds treated with rFVIIa alone, 86.0% (147/171) with AF alone, 84.2% (64/76) with rFVIIa + AF, 75.7% (162/214) with PT ± AF, and 73.3% (33/45) with rFVIIa + PT ± AF (Table 2B). This evidence concerns the gene F2 and atrial fibrillation.